Central Nervous System Demyelination Associated With Tofacitinib Use in Alopecia Areata: A Case Report and Literature Review

    May 2026 in “ Journal of Neurosciences in Rural Practice ”
    Patel Rushikumar Piyush, Balambighai Balaji, Jawahar Marimuthu
    Studysummary This case report describes a 23-year-old woman with alopecia areata who developed new central nervous system demyelination after starting tofacitinib therapy; while the drug was associated with this neurological event, causality is not confirmed. The demyelination was reversible upon stopping the medication and administering corticosteroids.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Therapeutic Potential of Oral Tofacitinib in Alopecia Areata: A Retrospective Study International Journal of Research in Dermatology · 2024
    2. New Developing Multiple Sclerosis in a Patient Using Tofacitinib Due to Alopecia Areata Dermatologic Therapy · 2022
    3. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016